The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
Abstract
Purpose: In early clinical trials with patients receiving highly emetogenic chemotherapy, the neurokinin antagonist aprepitant significantly enhanced the efficacy of a standard antiemetic regimen consisting of a type-three 5-hydroxytryptamine antagonist and a corticosteroid. This multicenter, randomized, double-blind, placebo-controlled phase III study was performed to establish definitively the superiority of the aprepitant regimen versus standard therapy in the prevention of chemotherapy-induced nausea and vomiting (CINV). Patients and Methods: Patients receiving cisplatin ≥ 70 mg/m 2 for the first time were given either standard therapy (ondansetron and dexamethasone on day 1; dexamethasone on days 2 to 4) or an aprepitant regimen (aprepitant plus ondansetron and dexamethasone on day 1; aprepitant and dexamethasone on days 2 to 3; dexamethasone on day 4). Patients recorded nausea and vomiting episodes in a diary. The primary end point was complete response (no emesis and no rescue therapy) on days 1 to 5 postcisplatin, analyzed by a modified intent-to-treat approach. Treatment comparisons were made using logistic regression models. Tolerability was assessed by reported adverse events and physical and laboratory assessments. Results: The percentage of patients with complete response on days 1 to 5 was significantly higher in the aprepitant group (72.7% [n = 260] v 52.3% in the standard therapy group [n = 260]), as were the percentages on day 1, and especially on days 2 to 5 (P < .001 for all three comparisons). Conclusion: Compared with standard dual therapy, addition of aprepitant was generally well tolerated and provided consistently superior protection against CINV in patients receiving highly emetogenic cisplatin-based chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The distribution of substance P and 5‐hydroxytryptamine in the central nervous system of the dog
Amin, A. H., Crawford, T. B. B., & Gaddum, J. H. (1954) · The Journal of Physiology · doi:10.1113/jphysiol.1954.sp005229 · Cited by 704
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., Clark-Snow, R., Gill, D. P., Groshen, S., Grunberg, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2971 · Cited by 664
Self-citationProposal for classifying the acute emetogenicity of cancer chemotherapy.
Hesketh, P. J., Kris, M. G., Grunberg, S. M., Beck, T., Hainsworth, J. D., Harker, G., Aapro, M. S., Gandara, D., & Lindley, C. M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.103 · Cited by 605
Self-citationPoli‐Bigelli, S., Rodrigues‐Pereira, J., Carides, A. D., Julie Ma, G., Eldridge, K., Hipple, A., Evans, J. K., Horgan, K. J., Lawson, F., & On behalf of the Aprepitant Protocol 054 Study Group (2003) · Cancer · doi:10.1002/cncr.11433 · Cited by 564
Self-citationPatient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
de Boer-Dennert, M., de Wit, R., Schmitz, P., Djontono, J., v Beurden, V, Stoter, G., & Verweij, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.507 · Cited by 378
Self-citationReduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
Navari, R. M., Reinhardt, R. R., Gralla, R. J., Kris, M. G., Hesketh, P. J., Khojasteh, A., Kindler, H., Grote, T. H., Pendergrass, K., Grunberg, S. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400304 · Cited by 370
Self-citationQuality of life consequences of chemotherapy-induced emesis
Lindley, C. M., Hirsch, J. D., O'Neill, C. V., Transau, M. C., Gilbert, C. S., & Osterhaus, J. T. (1992) · Quality of Life Research · doi:10.1007/bf00434947 · Cited by 257
Hesketh, P. J., Van Belle, S., Aapro, M., Tattersall, F. D., Naylor, R. J., Hargreaves, R., Carides, A. D., Evans, J. K., & Horgan, K. J. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00674-3 · Cited by 247
Self-citationCampos, D., Pereira, J. R., Reinhardt, R. R., Carracedo, C., Poli, S., Vogel, C., Martinez-Cedillo, J., Erazo, A., Wittreich, J., Eriksson, L.-O., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1759 · Cited by 219
Self-citationChawla, S. P., Grunberg, S. M., Gralla, R. J., Hesketh, P. J., Rittenberg, C., Elmer, M. E., Schmidt, C., Taylor, A., Carides, A. D., Evans, J. K., et al. (2003) · Cancer · doi:10.1002/cncr.11320 · Cited by 217
Self-citation
Cited by
Chemotherapy-Induced Nausea and Vomiting
Hesketh, P. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706547 · Cited by 827
Self-citationAmerican Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
Kris, M. G., Hesketh, P. J., Somerfield, M. R., Feyer, P., Clark-Snow, R., Koeller, J. M., Morrow, G. R., Chinnery, L. W., Chesney, M. J., Gralla, R. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9591 · Cited by 740
Self-citationRoila, F., Herrstedt, J., Aapro, M., Gralla, R. J., Einhorn, L. H., Ballatori, E., Bria, E., Clark-Snow, R. A., Espersen, B. T., Feyer, P., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq194 · Cited by 680
Self-citationAntiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting
Navari, R. M., & Aapro, M. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1515442 · Cited by 477
Warr, D. G., Hesketh, P. J., Gralla, R. J., Muss, H. B., Herrstedt, J., Eisenberg, P. D., Raftopoulos, H., Grunberg, S. M., Gabriel, M., Rodgers, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.050 · Cited by 463
Self-citationCisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
Fennell, D. A., Summers, Y., Cadranel, J., Benepal, T., Christoph, D. C., Lal, R., Das, M., Maxwell, F., Visseren-Grul, C., & Ferry, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.003 · Cited by 382
(2006) · Annals of Oncology · doi:10.1093/annonc/mdj078 · Cited by 323
Navari, R. M., Gray, S. E., & Kerr, A. C. (2011) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2011.05.002 · Cited by 319
Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy
Ständer, S., Siepmann, D., Herrgott, I., Sunderkötter, C., & Luger, T. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010968 · Cited by 293
Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.013 · Cited by 286
Self-citationWu, Y., Loper, A., Landis, E., Hettrick, L., Novak, L., Lynn, K., Chen, C., Thompson, K., Higgins, R., Batra, U., et al. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.08.001 · Cited by 275
Cancer cachexia—pathophysiology and management
Suzuki, H., Asakawa, A., Amitani, H., Nakamura, N., & Inui, A. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0787-0 · Cited by 268
Hargreaves, R., Ferreira, J. C. A., Hughes, D., Brands, J., Hale, J., Mattson, B., & Mills, S. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05961.x · Cited by 102
Aprepitant: A Novel Antiemetic for Chemotherapy-Induced Nausea and Vomiting
Massaro, A. M., & Lenz, K. L. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e242 · Cited by 73
Ständer, S., & Luger, T. A. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-662-44605-8_14 · Cited by 67
Ray, A. P., Griggs, L., & Darmani, N. A. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.07.028 · Cited by 40
“NK1 antagonists alone are ineffective against either phase of CIV [19,34], but potentiate antiemetic efficacy when combined with standard antiemetics [18].”
BackgroundFosaprepitant for the prevention of chemotherapy-induced nausea and vomiting
Ruhlmann, C. H., & Herrstedt, J. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.199 · Cited by 16
Metadata
- Authors
- Hesketh, P. J., Grunberg, S. M., Gralla, R. J., Warr, D. G., Roila, F., de Wit, R., Chawla, S. P., Carides, A. D., Ianus, J., Elmer, M. E., Evans, J. K., Beck, K., Reines, S., & Horgan, K. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-11-15
- Volume
- 21
- Issue
- 22
- Pages
- 4112-4119
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2165395427
- Cited by
- 779
- References
- 21
- FWCI
- 30.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.